Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Injectable Agent Makes Cancerous Cells Visible During Surgery

By HospiMedica International staff writers
Posted on 01 Feb 2016
Results from a trial published on January 6, 2015, in the journal Science Translational Medicine show how a new injectable agent can be used during soft-tissue sarcoma or breast cancer surgery to identified remnants of cancerous tissue.

Cancer surgeons use Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scans as guides during excision of tumors and surrounding tissue, however traces of cancerous tissue around the tumor remain undetected and as a result are not removed, leading to additional surgery later, and radiation therapy.

The trial was carried out at Duke University Medical Center (Durham NC, USA) and included 15 patients undergoing surgery for soft-tissue sarcoma or breast cancer. More...
The researchers tested the new injectable agent called LUM015 that makes tumor cells visible by causing fluorescence, and enables surgeons to find and take out all cancerous tissue in one operation.

The research into the new imaging technology was made possible by a collaboration between scientists at Duke University Medical Center, Massachusetts Institute of Technology (MIT; Cambridge, MA, USA), and a company called Lumicell (Wellesley, MA, USA).

As a next step, researchers at Massachusetts General Hospital are evaluating the efficacy and safety of LUM015 and the imaging technology in a trial with 50 women suffering from breast cancer. After that, the researchers plan to verify that the technology can reduce the number of second operations following surgery for the removal of breast cancer.

David Kirsch, MD, PhD, professor at Duke University School of Medicine, and senior author of the study, said. “At the time of surgery, a pathologist can examine the tissue for cancer cells at the edge of the tumor using a microscope, but because of the size of cancer it’s impossible to review the entire surface during surgery. The goal is to give surgeons a practical and quick technology that allows them to scan the tumor bed during surgery to look for any residual fluorescence.”

Related Links:

Duke University Medical Center
Massachusetts General Hospital
Lumicell



Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Glucose Meter
StatStrip®
New
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: 123RF

AI Platform Screens for Amyloid Cardiomyopathy Using ECG Images

Amyloid cardiomyopathy is a heart disease caused by deposits of misfolded proteins in the cardiac muscle. It is often missed until patients develop serious complications such as heart failure.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.